← board
BRNS
Barinthus Biotherapeuticsdistress 3/10 · well-funded / low risk$0.600%today-70% from 52w high
Infectious Disease 1Oncology 1
Lead: chronic hepatitis B · target PD-1 · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$66M
Runway
1.8 yrs
Shares 1y
+0%
Price & events
-17.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-10.4%
1W
-10.4%
1M
-6.1%
3M
-16.8%
6M
-68.6%
1Y
-58.6%
2Y
-95.9%
5Y
-95.7%
All
Overview
- Market Cap
- $24.51M
- Volume
- 4.28K
- 52 Week Range
- $0.54 – $1.97
- Total Shares
- 40.85M
- Float Shares
- 27.26M
- Short %
- 0.18%
- % Held by Insiders
- 19.81%
- % Held by Institutions
- 44.30%
- RVOL
- 0.09x
- Beta
- -0.40
Pipeline stages · 1 programs
ChAdOx1-HBV, MVA-HBV, NivolumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-01-13 | Phase 2 | ChAdOx1-HBV, MVA-HBV, Nivolumab | Chronic Hepatitis B | 121 | completed |
| 2025-02-05 | Phase 1/2 | ChAdOx1-PCAQ, MVA-PCAQ | Prostate Cancer | 22 | terminated |
Catalyst news & presentations · 3
- 2025-09-29partnershipEntry into Merger Agreement to combine with Clywedog Therapeutics via Topco.SEC 8-K
- May 7-10, 2025conferencedata presentationsecondaryPhase 2imdusiran, VTP-300 · End of study data for imdusiran + VTP-300 + nivolumab combinationSEC 8-K
- May 7-10, 2025conferencedata presentationsecondaryPhase 2VTP-300 · Preliminary analysis of VTP-300 + low-dose nivolumab shows HBsAg reductionsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-11-17HC Wainwright & Co.Buy
- 2025-03-21HC Wainwright & Co.Buy
- 2025-01-13HC Wainwright & Co.Buy
- 2024-11-19HC Wainwright & Co.Buy
- 2024-11-08HC Wainwright & Co.Buy
- 2024-10-01HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-02Barinthus Biotherapeutics (BRNS) Sinks Further as Shares Test Critical Support Near $0.58 - Flat Correction - dars.gov.et
- 2026-07-01BRNS Q1 2026 Earnings: Beats High EPS Bar Amid Pre-Revenue Stage - Revenue Beat Analysis - dars.gov.et
- 2026-07-01BRNS Q1 2026 Earnings: Beats High EPS Bar Amid Pre-Revenue Stage - Subscription Growth Report - dars.gov.et
- 2026-07-01BRNS Q1 2026 Earnings: Beats High EPS Bar Amid Pre-Revenue Stage - Quarterly Earnings - Bölüm Sonu Canavarı
- 2026-06-28Enterprise value to revenue forward of Barinthus Biotherapeutics plc – NASDAQ:BRNS - TradingView
- 2026-06-26BRNS Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25BRNS Q1 2026 Earnings: Narrower Net Loss Beats Consensus Amid Pipeline Progress - Mid-Term Outlook - DonanımHaber
- 2026-06-23BRNS Q1 2026 Earnings: Beats EPS Estimates Amid Narrower Loss, Stock Declines 4% - Annual Report - DonanımHaber
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.